I don't think it's so clear cut. First of all with these drugs it's actually impossible to say what percentage of patients our new drugY will work on or who they are. Instead they're going to be marketed to everyone. In fact the article makes the case that these faster approvals may actually slow down our ability to get this information:
The FDA also increasingly allows drugmakers to claim success in trials based on proxy measurements — such as shrunken tumors — instead of clinical outcomes like survival rates or cures, which take more time to evaluate. In return for accelerated approval, drug companies commit to researching how well their drugs work after going on the market. But these post-marketing studies can take 10 years or longer to complete, leaving patients and doctors with lingering questions about safety and benefit.
So what, there's going to be a 10 year period where patients are unable to evaluate what their best shot at treatment is? We often forget that markets and rational decision-making require good information to produce good outcomes. Allowing drugs into the market that are opaque and expensive isn't going to make things better for patients, it's going to make it worse.